Patent · US Active

ERBB receptor inhibitors

US11447492B2 · kind B2 · utility

0Cited by

1References

15Claims

0Family size

Assignee

Dizal (Jiangsu) Pharmaceutical Co., Ltd. · CN

Inventors

Zhengtao LI · Shanghai, CN
Wei Zhong · Pullman, US
Jiabing Wang · Lansdale, US
Qingbei Zeng · Shanghai, CN
Honchung Tsui · Shanghai, CN
Zhenfan Yang · Shanghai, CN
Xiaolin Zhang · Singapore, SG

Key dates

Filing date	Sep 23, 2020
Grant date	Sep 20, 2022
Priority date	—
Expiry date	Sep 23, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are quinazoline compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds which are useful in treating diseases associated ErbBs. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.